In vitro activity of U-57930E, a new clindamycin analog, against aerobic gram-positive bacteria.
AUTOR(ES)
Ahonkhai, V I
RESUMO
The in vitro activity of U-57930E, a new clindamycin analog, against aerobic gram-positive cocci was studied by microdilution broth susceptibility tests and compared with the activities of clindamycin, vancomycin, oxacillin, and ampicillin. U-57930E inhibited methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus viridans at concentrations of less than or equal to 1 microgram/ml. This degree of activity was generally slightly less than that of the other antimicrobial agents tested. Methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, penicillin-resistant Streptococcus pneumoniae, and enterococci were resistant to U-57930E. At the concentrations used, U-57930E exhibited bactericidal activity against most susceptible organisms, and a minimal effect of inoculum size was noted.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=182043Documentos Relacionados
- In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.
- In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteria.
- In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.
- Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
- In vitro activities of two glycylcyclines against gram-positive bacteria.
